万泰生物：重组呼吸道合胞病毒疫苗（CHO 细胞）临床试验申请获得受理

Core Viewpoint - The company announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has received the acceptance notice for the clinical trial application of the "Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)" from the National Medical Products Administration [1] Group 1 - The vaccine is jointly developed by Xiamen University and Xiamen Wantai Canghai Biotechnology Co., Ltd., utilizing genetic engineering recombinant technology and produced using CHOZN cells [1] - If successfully developed and launched, this product will enrich the company's product portfolio and enhance its market competitiveness [1] - The process from research and development to market launch involves many stages, and there is uncertainty regarding whether it will receive approval for clinical trials and progress smoothly [1] Group 2 - The acceptance of the clinical trial application notice will not have a significant impact on the company's recent performance [1]